Journal articles on the topic 'Sandow Group'
To see the other types of publications on this topic, follow the link: Sandow Group.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Sandow Group.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Mikhalsky, E. V., D. A. Tkacheva, S. G. Skublov, G. L. Leitchenkov, N. V. Rodionov, I. N. Kapitonov, and E. L. Kunakkuzin. "Low-grade Sandow Group metasediments of the Denman Glacier area (East Antarctica): Chemical composition, age and provenance from U–Pb detrital zircon data, with some palaeotectonic implications." Polar Science 26 (December 2020): 100587. http://dx.doi.org/10.1016/j.polar.2020.100587.
Full text
2
Rutan, J. Scott. "Sandor Ferenczi’s Contributions to Psychodynamic Group Therapy." International Journal of Group Psychotherapy 53, no. 3 (July 2003): 375–84. http://dx.doi.org/10.1521/ijgp.53.3.375.42825.
Full text
3
Fraser, Maia, Leonid Polterovich, and Daniel Rosen. "On Sandon-type metrics for contactomorphism groups." Annales mathématiques du Québec 42, no. 2 (October 16, 2017): 191–214. http://dx.doi.org/10.1007/s40316-017-0092-z.
Full text
4
Eaton, Helen. "Sandawe." Journal of the International Phonetic Association 36, no. 2 (December 2006): 235–42. http://dx.doi.org/10.1017/s0025100306002647.
Full textAbstract:
The Sandawe language is spoken in the Kondoa district of central Tanzania by approximately 40,000 people. Sandawe has been widely assumed to be a member of the Khoisan language family, but recent research has cast doubt on the position that such a family exists (Güldemann & Vossen 2000). The Sandawe language can be divided into an eastern variety and a western variety. The differences between these two varieties are slight and gradual. The orthography used in the following description was decided upon in 2002 by a group of Sandawe speakers representing different parts of the language area. Early research on Sandawe phonetics and phonology was undertaken by Dempwolff (1916) and Copland (1938). More recent studies are found in Tucker & Bryan (1977), Elderkin (1989, 1992), Wright, Maddieson, Ladefoged & Sands (1995), Maddieson, Ladefoged & Sands (1999) and Hunziker, Hunziker & Eaton (2005).
5
Aurer, Igor, Ozren Jaksic, Sandra Bašić-Kinda, Stefan Mrdenovic, Slobodanka Ostojic Kolonic, Dominik Lozic, Hrvoje Holik, et al. "Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases." Blood 138, Supplement 1 (November 5, 2021): 3553. http://dx.doi.org/10.1182/blood-2021-149613.
Full textAbstract:
Abstract Patients with lymphoid malignancies are at increased risk of death due to COVID19. Currently, it is not completely clear whether this is mainly due to disease biology or to anti-lymphoma treatment and whether the prognosis of infection differs in patients treated with different therapies. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is not known whether this risk is affected by the choice of the antibody. To study these questions, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID19 between October 2020 and April 2021. Death during infection was considered as due to COVID19. Patients were considered to have prolonged disease if they were continuously or repetitively positive by PCR for more than 6 weeks. Percentage of patients with prolonged disease was calculated based on the number of patients with available data who were alive 6 weeks after beginning of infection. Treatment regimens were divided into those containing purine analogues (PA), mainly bendamustine and fludarabine, standard-dose chemotherapy without PA (e.g. CHOP, CVP, chlorambucil, etc.), high-dose chemotherapy without PA (e.g. DHAP, ICE, etc.), B-cell receptor inhibitors (iBCR) and venetoclax. We identified 314 patients, 20-88 years old (median 66), 180 male and 134 female; 75 were untreated, 61 off treatment and 178 on treatment (Table). Eleven (15%) untreated patients died; 10% had prolonged infection none of whom died. Ten (16%) off-treatment patients died; 9% had prolonged infection none of whom died. In the on-treatment group 6 (3%) are still prolonged positive, 110 (62%) recovered and 62 (35%) died; 42% had prolonged infection of whom 47% recovered and 42% died. The single allografted patient died as did both patients treated with CAR-T cells after prolonged infection. We analyzed prognostic factors for lethal and prolonged infection in the 175 conventionally treated patients. Disease type, use of anti-CD20 monoclonal antibodies, prior autologous stem-cell transplantation (ASCT) and line of treatment did not significantly affect mortality. Mortality was higher in older (p=0.0078) and those treated with PA in comparison to standard-dose chemotherapy without PA and iBCR (47% vs. 26%, p=0.012). The effect of anti-lymphoma therapy on mortality was similar in all age groups. All of the 7 patients who received neither cytotoxic agents nor iBCR (4 were on rituximab monotherapy, 2 on cyclosporine and 1 on vemurafenib) recovered, none had prolonged infection. Prolonged COVID19 was significantly more frequent in patients treated with anti-CD20 monoclonal antibodies (p=0.012), especially obinutuzumab (67% in comparison to 42% in those treated with rituximab and 21% in those treated without anti-CD20 antibodies). Treatment with PA also increased the risk of prolonged disease (69% vs. 25-45% in other groups, p=0.012). The effect of PA on prolonged infection was similar in patients treated with rituximab and obinutuzumab. Age, prior ASCT and treatment line did not significantly affect risk of prolonged infection. Our data suggest that the type of anti-lymphoma therapy is, besides age, a main determinant of prognosis of COVID19 in patients with lymphoid malignancies. Use of purine analogues, such as bendamustine and fludarabine, is related to increased risk of lethal and/or prolonged COVID19. These drugs should probably be avoided in patients with indolent NHL and CLL, diseases for whom other effective treatments are available, during the current pandemia. Anti-CD20 monoclonal antibodies seem to have a smaller effect on mortality, with obinutuzumab increasing the risk of prolonged disease, but not of death, in comparison to rituximab. Figure 1 Figure 1. Disclosures Aurer: takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Swixx/BMS: Honoraria; Teva/Pilva: Honoraria; Abbvie: Consultancy, Honoraria; sanofi genzyme: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Eusapharma: Consultancy, Honoraria. Jaksic: Roche, Oktal-Pharma/Celtrion, Sandoz: Consultancy, Honoraria. Mrdenovic: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria. Ostojic Kolonic: Roche, Oktal-Pharma/Celtrion, Sandoz: Consultancy, Honoraria. Lozic: Roche, Oktal-Pharma/Celtrion, Sandoz: Consultancy, Honoraria. Holik: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria. Novakovic Coha: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria. Bernes: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria. Krecak: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria. Moric Peric: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria. Mitrovic: Roche, Oktal-Pharma/Celtrion, Sandoz: Honoraria.
6
Huggett, J. M., A. S. Gale, and C. Hazell. "Early diagenesis of the lower Vectis Formation, Wealden Group Lower Cretaceous, Barremian), Sandown, Isle of Wight." Proceedings of the Geologists' Association 129, no. 6 (December 2018): 782–89. http://dx.doi.org/10.1016/j.pgeola.2018.08.004.
Full text
7
Sasikumar, Sheetal, and Jaisurya Jaisukhalal. "Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) syndrome associated with two heterozygous POLG mutations." Nepal Journal of Neuroscience 19, no. 3 (November 9, 2022): 56–57. http://dx.doi.org/10.3126/njn.v19i3.45977.
Full textAbstract:
Polymerase gamma is a mitochondrial DNA polymerase, that is responsible for the replication of the mitochondrial DNA (mtDNA). It is encoded by the POLG gene, on chromosome 15q25. Various mutations in this gene have been described, with varied phenotypic manifestations. The triad of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO) has been reported only in a small group of patients with POLG mutations. We report the case of a male, who presented with phenotype of SANDO syndrome and and was found to have two pathogenic, heterozygous mutations in the POLG gene.
8
Loganathan, N., H. G. Poulos, and K. J. Xu. "Ground and Pile-Group Responses Due to Tunnelling." Soils and Foundations 41, no. 1 (February 2001): 57–67. http://dx.doi.org/10.3208/sandf.41.57.
Full text
9
Beaudoin, Georges, D. F. Sangster, and C. I. Godwin. "Isotopic evidence for complex Pb sources in the Ag–Pb–Zn–Au veins of the Kokanee Range, southeastern British Columbia." Canadian Journal of Earth Sciences 29, no. 3 (March 1, 1992): 418–31. http://dx.doi.org/10.1139/e92-037.
Full textAbstract:
In the Kokanee Range, more than 370 Ag–Pb–Zn–Au vein and replacement deposits are hosted by the Middle Jurassic Nelson batholith and surrounding Cambrian to Triassic metasedimentary rocks. The Kokanee Range forms the hanging wall of the Slocan Lake Fault, an Eocene, east-dipping, low-angle normal fault. The Pb isotopic compositions of galenas permit the deposits to be divided into four groups that form linear arrays in tridimensional Pb isotopic space, each group having a distinct geographic distribution that crosses geological boundaries. The Kokanee group Pb is derived from a mixture of local upper crustal country rocks. Ainsworth group Pb and Sandon group Pb plot along a mixing line between a lower crustal Pb reservoir and the upper crustal Pb reservoir. The Ainsworth group Pb isotopic signature is markedly lower crustal, whereas the Sandon group Pb is slightly lower crustal. The Bluebell group Pb plots along a mixing line between a depleted upper mantle Pb reservoir and the lower crustal Pb reservoir.The geographic distribution and the Pb isotopic composition of each group probably reflect deep structures that permitted mixing of lower crustal, upper crustal, and mantle Pb by hydrothermal fluids. Segments of, or fluids derived from, the lower crust and the upper mantle were leached by, or mixed with, evolved meteoric water convecting in the upper crust. Fracture permeability, hydrothermal fluid flow, and mineralization resulted from Eocene crustal extension in southeastern British Columbia.
10
Wolberg, Donald L. "Fifth notice of transfer of specimens figured by Rousseau H. Flower." Journal of Paleontology 65, no. 2 (March 1991): 338–39. http://dx.doi.org/10.1017/s0022336000020643.
Full textAbstract:
This notice is the fifth in a series recording the transfer of fossils described by Rousseau H. Flower (1913-1988) to the Smithsonian Institution and the U.S. National Museum. During a long, productive, and colorful career, Rousseau described more than 400 new fossil taxa (Wolberg, 1988). Most of Rousseau's fossils have been maintained in the collections of the New Mexico Bureau of Mines and Mineral Resources. The fossils in this transfer were sent to Rousseau in 1952 by William J. Sando, then a graduate student at Johns Hopkins University, who collected them during his research on the Beekmantown Group of Maryland (Sando, 1957). In 1955, Rousseau submitted a manuscript to theJournal of Paleontologyand this was published in 1956. Some controversy seems to have surrounded the publication of the paper; we have found a file of correspondence related to that publication and it is very “Roweresque” in content. In addition, Rousseau cataloged the Sando fossils into the NMBM&MR's collection, but from the associated correspondence there seems to be little doubt but that the collection was intended to be reposited in the Smithsonian.
11
VIȚĂLARU, BOGDAN ALEXANDRU, MĂDĂLIN ION RUSU, CARMEN MIHAI, and ALEXANDRU CHIOTOROIU. "A comparison between Chinese finger trap and Roman sandals suturein peritoneal dialysis catheters for chronic kidney disease appliedin veterinary medicine." Industria Textila 71, no. 01 (February 27, 2020): 8–11. http://dx.doi.org/10.35530/it.071.01.1722.
Full textAbstract:
Catheters designed for chronic peritoneal dialysis have Dacron cuffs meant to protect the patient against bacterialinfection and catheter migration that may lead to a high peritonitis rate in case of extensive use. Peritoneal catheter isfixed by suturing the skin with a non-absorbable monofilament thread ranging from 4/0 to 2/0. The two types of suturesmost commonly used are Roman sandal and Chinese fingertrap. In this study we selected 44 dogs, both males andfemales with CKD (Chronic Kidney Disease) undergoing peritoneal dialysis. We have created two groups: first group(A) of 22 patients were treated using a peritoneal catheter for chronic treatment, with Roman sandal suture and thesecond group of 22 patients (B) were treated using a peritoneal catheter for chronic treatment, with Chinese fingertrapsuture. All patients from group A kept the catheters until the end of the treatment (22 out of 22, 100%). Eight out of14 patients (36.36%) from group B needed secondary suture. Four out of the eight patients (18.18%) form the group Bneeded secondary suturing because of the suture weakening. Three out of the eight patients (13.63%) form the groupB needed secondary suturing of the catheter because of the skin rupture at the initial placement spot of the suture. Oneof the eight patients (4.54%) form the group B needed secondary suturing of the catheter because of the catheterreplacement, due to the weakening of the suture and its lack of resistance to the aggression manifested by the patients
12
Martin, S. Rebecca. "Revisiting the ‘Slipper Slapper’ and other sculpture dedications in the clubhouse of the Poseidoniasts of Beirut." Journal of Greek Archaeology 2 (January 1, 2017): 253–82. http://dx.doi.org/10.32028/jga.v2i.586.
Full textAbstract:
In 1904 a team led by French archaeologist Marcel Bulard discovered a sculptural group on the island of Delos in a building owned by businessmen from the Phoenician city of Beirut (Figures 1–6; Map 1). This work, now known as the ‘Sandal Slapper’ or ‘Slipper Slapper’, dates to c. 100 BCE. It shows Aphrodite holding up one of her sandals, Pan holding onto to her, and Aphrodite’s son Eros flying overhead. The group’s goddess is a quotation of the now-lost, late-Classical Aphrodite of Knidos by Praxiteles (fl. 364/361 BCE). In its preliminary publication, Bulard described the work: ‘Le groupe représente Aphrodite, se défendant avec l’aide d’Éros contre les entreprises de Pan.’ This interpretation of the group’s narrative – a bawdy scene in which Aphrodite brandishes her sandal at Pan’s sexual advances – is now standard.
13
Saeedi, Hassan, Mehdi Rezaee, Aliyeh Daryabor, Mobina Khosrav, and Samira Hassan Pour. "Comparing the immediate effect of pneumatic and conventional knee braces on gait, satisfaction and pain in patients with knee medial osteoarthritis." International Journal of Therapy and Rehabilitation 29, no. 11 (November 2, 2022): 1–10. http://dx.doi.org/10.12968/ijtr.2021.0179.
Full textAbstract:
Background/aims Knee braces can change loading direction on knees in people with osteoarthritis, thereby reducing symptoms and progression of the disease. The aims of this study were to explore the immediate effect of two types of braces, a pneumatic knee brace with air pressure embedded in a sandal cuff (sandal cuff pressure) and a conventional knee brace on gait, pain and satisfaction during walking in patients with knee medial osteoarthritis. Methods A total of 28 patients with knee medial osteoarthritis were assigned to two groups, 14 patients used a conventional brace and 14 used a prototype brace with a pneumatic system, which was designed and fabricated by the authors, and followed the mechanism of variable pressures in the stance and swing phases of a gait cycle in a patient's knee. The gait parameters (walking self-selected speed, cadence, step length, knee range of motion, and maximum knee adduction moment, walking speed, cadence and step length) were measured with a Kistler force plate and Vicon motion analysis under two conditions: with and without brace for the conventional brace group, and under three conditions of no brace, brace with sandal cuff pressure, and brace without sandal cuff pressure for the pneumatic brace group. Patients' pain and satisfaction were also measured using a visual analogue scale and Likert scale respectively. Results Both groups showed a significant reduction in maximum knee adduction moment and pain wearing braces in comparison to no brace during walking (P<0.05). The knee range of motion was significantly decreased in the pneumatic brace group with and without sandal cuff pressure compared with no brace (P<0.001). No significant difference was found for any of the variables when using the pneumatic brace with and without sandal cuff pressure (P>0.05). In the between-group comparison, only patients' satisfaction was significantly reduced when using the pneumatic brace in both walking with (P=0.041) and without (P=0.02) sandal cuff pressure compared to those using the conventional brace. Conclusions Both conventional and pneumatic braces led to reduced knee adduction moment and pain in patients with knee osteoarthritis. However, using a pneumatic brace reduced the knee range of motion and satisfaction of patients, which could be because the brace was a prototype.
14
Schmalzing, M., H. Kellner, A. Askari, J. De Toro Santos, J. C. Vazquez Perez-Coleman, R. Foti, S. Jeka, et al. "POS0640 REAL-WORLD EFFECTIVENESS AND SAFETY OF GP2015 IN PATIENTS WITH RHEUMATIC DISEASES: FINAL RESULTS OF THE COMPACT STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 589–90. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1110.
Full textAbstract:
BackgroundCOMPACT is a non-interventional study evaluating the effectiveness and safety in patients (pts) with rheumatoid arthritis (RA), axial-spondyloarthritis (axSpA) or psoriatic arthritis (PsA) treated with GP2015 (an etanercept [ETN] biosimilar) in real-world conditions.ObjectivesWe present the effectiveness and safety data from the final analysis of the COMPACT study for all patient groups.MethodsPts aged ≥18 years on treatment with GP2015 were enrolled. Baseline visit corresponded with date of study inclusion and not with date of GP2015 treatment start. Pts were categorised based on prior treatment status: pts on clinical remission or low disease activity under treatment with reference ETN or biosimilar ETN (initial ETN: [iETN]) and switched to GP2015 (Group A) or pts who received non-ETN targeted therapies and switched to GP2015 (Group B) or biologic-naïve pts who started GP2015 after conventional therapy failure (Group C) or DMARD-naïve pts with recent diagnosis of RA considered suitable for treatment initiation with a biologic and started on treatment with GP2015 (Group D). Effectiveness assessments included Disease Activity Score 28-joint count Erythrocyte Sedimentation Rate (DAS28-ESR) or Ankylosing Spondylitis Disease Activity Score (ASDAS) until Month 12 after enrolment (baseline) in the study.ResultsOf the 1466 pts enrolled, 572 were switched from iETN (Group A), 171 were switched from other targeted therapies (Group B), 713 were biologic-naïve (Group C), and 10 were RA DMARD-naïve (Group D). Comorbidities were more frequent in pts with RA (68.7%,) followed by pts with PsA (59.4%) and axSpA (52.1%). After 12 months of treatment with GP2015, pts with RA or PsA achieved comparable DAS28-ESR scores irrespective of whether they switched from iETN, or from other targeted therapies or were biologic-naïve. At Month 12, the mean ASDAS scores were comparable between the treatment groups in pts with axSpA (Table 1). Across all pt groups, no major differences were observed in the disease activity scores between baseline and Month 12 that may be explained by the ongoing GP2015 treatment at the time of enrolment for an observed average of 138 days. Overall, the proportion of patients with at least one adverse event (AE) and serious AE (SAE) was 47.6% and 7.7% in pts who were switched from iETN, 56.7% and 9.9% in pts switched from other targeted therapies, 56% and 8.7% in biologic-naïve pts, and 60% and 0% in DMARD-naïve pts. Rate of injection site reaction was low across the groups (Figure 1).Table 1.Effectiveness outcomes in patients treated with GP2015Effectiveness outcomesGroup AGroup BGroup CGroup DOverall (A-D)RADAS28-ESR, n, mean (SD)N=295N=88N=451N=10N=844Baselinen=259n=70n=392n=8n=7292.5 (1.1)3.6 (1.3)3.3 (1.5)3.8 (1.2)3.0 (1.4)Month 12n=135n=47n=238n=2n=4222.5 (1.3)2.7 (1.0)2.8 (1.4)4.3 (2.5)2.7 (1.3)PsAN=117N=36N=135N=0N=288Baselinen=80n=30n=116-n=2262.1 (1.0)2.9 (1.6)2.9 (1.6)2.6 (1.5)Month 12n=32n=13n=60-n=1052.6 (1.9)2.6 (1.6)2.3 (1.4)2.4 (1.5)AxSpAASDAS, n, mean (SD)N=160N=47N=127N=0N=334Baselinen=77n=18n=59-n=1541.6 (0.6)1.8 (0.8)2.3 (0.9)1.9 (0.8)Month 12n=39n=8n=23-n=701.8 (0.9)1.9 (0.6)1.9 (1.0)1.8 (0.9)N, total number of patients in the treatment group; n, number of patients with available data at each time point, SD, standard deviationFigure 1.Overall safety outcomes in patients treated with GP2015Figure 1 represents the adverse events reported during GP2015 treatment.N, total number of patients in the treatment; n, number of patients in each treatment groupConclusionThe results show comparable disease activity scores between pts who were switched from iETN, pts switched from other targeted therapies and biologic-naïve pts after 12 months of treatment with GP2015. No impact on the effectiveness of ETN was observed in pts with RA, axSpA or PsA who switched to GP2015. No new safety signals were reported.Disclosure of InterestsMarc Schmalzing Speakers bureau: Novartis, AbbVie, Chugai/Roche, Janssen-Cilag, Lilly, Consultant of: AstraZeneca, Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer/Ingelheim, Grant/research support from: Chugai/Roche, Boehringer/Ingelheim, Celgene, Medac, Herbert Kellner: None declared, Ayman Askari: None declared, Javier de Toro Santos: None declared, JULIO CESAR VAZQUEZ PEREZ-COLEMAN Speakers bureau: Sandoz, Abbvie, Sanofi, Fresenius, Rosario Foti Speakers bureau: Abbivie, Gilead, Lilly, Pfizer, UCB, Roche, Novartis, Pfizer, UCB, Sławomir Jeka: None declared, Boulos Haraoui Consultant of: Abbvie, Amgen, Fresenius Kabi, Lilly and Pfizer, Grant/research support from: Abbvie, Amgen, Fresenius Kabi, Lilly and Pfizer, Yannick Allanore Consultant of: Sandoz Hexal, Mylan, Astra-Zeneca, Masiur Rahman Employee of: Sandoz Hexal AG, Fabricio Furlan Employee of: Sandoz Hexal AG, Sohaib HACHAICHI Employee of: Sandoz Hexal AG, Tom Sheeran Speakers bureau: Pfizer, UCB, Roche, Consultant of: Novartis, Pfizer, Grant/research support from: Novartis, UCB, Roche
15
Jacobsen, Jógvan í. Lon. "Unges dialektbrug i bygden Sandur på Færøerne." Oslo Studies in Language 11, no. 2 (January 21, 2021): 173–87. http://dx.doi.org/10.5617/osla.8497.
Full textAbstract:
In this article, dialect changes and variation among young schoolchildren in the island of Sandoy in the Faroe Islands are discussed. The fieldwork was made by a group of students at the University of the Faroe Islands in November 2019 under the guidance of this article’s author. The informants are two groups of 10 and 15 year old schoolchildren. By examining the young generation, we can get information about the ‘state of health’ of the dialect. Here three dialectal variables are examined: (i) The variation of definite and indefinite form of words for family members, for instance the dialectal form mamman ‘the mother’ and the Central Faroese form mamma ‘mother’; (ii) Personal and possessive pronouns in 1st and 2nd person plural in oblique case, for instance the dialect form [o:gʊn] ‘us’ and the Central Faroese form [ɔʰk:ʊn] ‘us’; (iii) The pronunciation of short ó with the dialectal variant [ɔ] and the Central Faroese form [œ], for instance [fɔlk] resp. [fœlk] ‘people’.
The first variable shows clearly a tendency towards dialect change in the young generation: the indefinite forms are much more frequent than the dialect counterpart. The use of the pronouns shows a relatively high degree of variation: the dialect forms are more frequently used by the 10 than the 15 year old pupils. The pronunciation of short ó shows variation to a large extent. Here we see the same pattern as we saw for variable 2: the youngest pupils are more likely to use the dialect¬al form [ɔ] than the older ones. On the other hand, variation is much more common in the group of 15 year old pupils.
This study shows both stability and change in the dialect of children in Sandoy: Stability in use of the dialectal forms of the personal and possessive pro¬nouns, and variation and change in the two other variables. In a couple of years an underwater tunnel will connect the island of Sandoy with the central part of the islands. In a future scenario this dialect study opens the possibility for comparative studies of the dialect of Sandoy before and after the opening of the tunnel.
16
Осипов, Николай Николаевич. "CONCEPT OF “NATIVE LAND” IN SONG POETRY OF SANDOR AKSAR." Bulletin of the Chuvash State Pedagogical University named after I Y Yakovlev, no. 4(109) (January 26, 2021): 104–13. http://dx.doi.org/10.37972/chgpu.2020.109.4.012.
Full textAbstract:
Статья посвящена изучению концепта «родной край» в песенной поэзии. В работе на основе анализа текстов песен Сандора Аксара, вошедших в книги «Акашсем те ишеддё перле» («И лебеди плавают парами»), «Саламладдё далтарсем пире» («Нас приветствуют звезды») и в другие его сборники, определяется место темы малой родины в творчестве поэта, раскрывается ее своеобразие. В работе исследуется полифункциональность образов родного края, показывается роль автора (лирического «я») в поэтических произведениях. Обращается внимание на воспитательные функции и художественные особенности стихотворений. Рассматриваются основные смыслы и представления, связанные с концептом «родной край», и определяется группа ценностей, с которыми он традиционно ассоциируется в языковом и поэтическом сознании Сандора Аксара. Для описания концепта «родной край» нами выделяются разнообразные художественные средства выразительности и ключевые образы, отражающие и репрезентирующие концепт, рассматриваются универсальные и специфические приемы и средства выражения концепта в творчестве поэта-песенника. The article is devoted to the study of the concept of “native land” in song poetry. Based on the analysis of the lyrics of Sandor Aksar included in the books “Akashsem te isheshe perle” (“and swans swim in pairs”), “Salamlashe shaltarsem pire” (“we are greeted by the stars”) and other collections, the author determines the place of the theme of the small homeland in the poet’s work and reveals its originality. The paper explores the polyfunctionality of images of the native land, shows the role of the author (the lyrical “I”) in poetic works. Attention is drawn to the educational functions and artistic features of the poems. The article considers the main meanings and ideas associated with the concept of “native land” and determines the group of values with which it is traditionally associated in the linguistic and poetic consciousness of Sandor Aksar. To describe the concept of “native land”, the author selects a variety of artistic means of expression and key images-symbols that reflect and represent the concept, considers universal and specific methods and means of expression of the concept in the works of the lyric writer.
17
Zhang, Feng, and Makoto Kimura. "Numerical Prediction of the Dynamic Behaviors of an RC Group-Pile Foundation." Soils and Foundations 42, no. 3 (June 2002): 77–92. http://dx.doi.org/10.3208/sandf.42.3_77.
Full text
18
Kong, L. G., and L. M. Zhang. "Nonlinear Analysis of Torsionally Loaded Pile Groups." Soils and Foundations 49, no. 2 (April 2009): 275–86. http://dx.doi.org/10.3208/sandf.49.275.
Full text
19
Basile, Francesco. "Nonlinear Analysis of Torsionally Loaded Pile Groups." Soils and Foundations 50, no. 2 (April 2010): 337–40. http://dx.doi.org/10.3208/sandf.50.337.
Full text
20
Kong, L. G., and L. M. Zhang. "Nonlinear Analysis of Torsionally Loaded Pile Groups." Soils and Foundations 50, no. 2 (April 2010): 341. http://dx.doi.org/10.3208/sandf.50.341.
Full text
21
Kitazume, Masaki, and Kenji Maruyama. "External Stability of Group Column Type Deep Mixing Improved Ground Under Embankment Loading." Soils and Foundations 46, no. 3 (June 2006): 323–40. http://dx.doi.org/10.3208/sandf.46.323.
Full text
22
Kitazume, Masaki, and Kenji Maruyama. "Internal Stability of Group Column Type Deep Mixing Improved Ground Under Embankment Loading." Soils and Foundations 47, no. 3 (June 2007): 437–55. http://dx.doi.org/10.3208/sandf.47.437.
Full text
23
Schmalzing, M., A. Askari, T. Sheeran, D. Walsh, J. De Toro Santos, J. C. Vazquez Perez-Coleman, C. Both, F. Furlan, S. Hachaichi, and H. Kellner. "POS0608 SWITCHING OF TREATMENT FROM REFERENCE ETANERCEPT TO SANDOZ ETANERCEPT BIOSIMILAR IN PATIENTS WITH RHEUMATIC DISEASES: AN INTERIM ANALYSIS OF REAL-WORLD DATA FROM THE COMPACT STUDY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 540.1–540. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1490.
Full textAbstract:
Background:Sandoz etanercept (SDZ ETN) is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with SDZ ETN treatment in patients (pts) with rheumatoid arthritis (RA), axial-spondyloarthritis (axSpA) or psoriatic arthritis (PsA) in real-world conditions.Objectives:We have reported an interim analysis, with the effectiveness and safety data focusing on pts who were in clinical remission or low disease activity under treatment with reference ETN or biosimilar ETN other than SDZ ETN (initial ETN; iETN) and switched to SDZ ETN.Methods:Pts aged ≥18 years for whom treatment with SDZ ETN were initiated are being enrolled. Pts were categorized under four treatment groups based on prior treatment status: Group A,pts on clinical remission or low disease activity under treatment with iETN and switched to SDZ ETN; Group B, pts who received targeted therapies and switched to SDZ ETN; Group C, biologic naïve considered uncontrolled with conventional therapy; Group D, DMARD naïve with recent diagnosis of RA considered suitable for treatment initiation with a biologic and started on treatment with SDZ ETN. Effectiveness assessments included Disease Activity Score 28-joint count Erythrocyte Sedimentation Rate (DAS28-ESR) or Ankylosing Spondylitis Disease Activity Score (ASDAS) until Week 24 after enrollment (baseline; BL) in the study. Functional disability was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). The effectiveness and safety results are reported for the pts who switched from iETN (Group A).Results:Of the 1437 pts recruited (analysis cut-off date: 16 Oct, 2020), 567 pts were switched from iETN, 163 were switched from other targeted therapies, 697 were biologic-naïve, and 10 were RA DMARD-naïve. Among pts who switched from iETN, 51.5% had RA, followed by axSpA (28.0%) and PsA (20.5%). Comorbidities were more frequent in pts with RA (70.2%) followed by PsA (58.6%) and axSpA (49.7%); musculoskeletal and connective tissue disorders were reported in 31.8% and 15.7% of pts with RA and axSpA, respectively. At BL, whilst receiving iETN, the mean (SD) DAS28-ESR scores were 2.5 (1.1) and 2.1 (1.1) in pts with RA and PsA, respectively (figure 1). The mean change from BL in DAS28-ESR score at Week 24 after switch to SDZ ETN was -0.1 (1.1) and 0 (1.0) in pts with RA and PsA, respectively. In pts with axSpA, the mean (SD) ASDAS score was 1.5 (0.7) at BL; mean change from BL in ASDAS score at Week 24 was 0.1 (0.5). At BL, the mean (SD) HAQ-DI scores were 0.8 (0.7), 0.5 (0.7) and 0.5 (0.6) in pts with RA, PsA and axSpA, respectively. Overall, the proportion of patients with at least one adverse event (AE) was 37.3%, 33.6% and 25.8% in pts with RA, PsA and axSpA, respectively. Serious AEs were reported in 6.5%, 1.7% and 3.1% of pts with RA, PsA, and axSpA, respectively. Injections site reactions were reported in 2.7%, 0.9% and 1.3% of pts with RA, PsA and axSpA, respectively.Figure 1.Disease activity in patients who switched from iETN to SDZ ETNConclusion:The interim analysis results shows that switch from iETN to SDZ ETN does not impact the effectiveness of ETN in pts with RA, axSpA or PsA, without any new safety signals.Disclosure of Interests:Marc Schmalzing Speakers bureau: Novartis, AbbVie, Chugai/Roche, Janssen-Cilag, Lilly, Consultant of: AstraZeneca, Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer/Ingelheim, Grant/research support from: Travel grants: Chugai/Roche, Boehringer/Ingelheim, Celgene, Medac, Ayman Askari: None declared, Tom Sheeran Speakers bureau: Pfizer, UCB, Roche, Consultant of: Novartis, Pfizer, Grant/research support from: Novartis, UCB, Roche, David Walsh: None declared, Javier de Toro Santos: None declared, JULIO CESAR VAZQUEZ PEREZ-COLEMAN Speakers bureau: Sandoz, Abbvie, Sanofi, Fresenius, Charlotte Both Employee of: Sandoz employee Global Medical Affairs, Fabricio Furlan Employee of: Sandoz employee Global Medical Affairs, Sohaib HACHAICHI Employee of: Sandoz employee Global Medical Affairs, Herbert Kellner: None declared
24
Jeong, Sangseom, and Sooil Kim. "Interaction Factors for Pile Groups Due to Downdrag." Soils and Foundations 38, no. 2 (June 1998): 49–61. http://dx.doi.org/10.3208/sandf.38.2_49.
Full text
25
Coates, L. C., E. Soriano, N. Corp, H. Bertheussen, K. Callis-Duffin, C. Barbosa Campanholo, J. Chau, et al. "OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 139–40. http://dx.doi.org/10.1136/annrheumdis-2021-eular.4091.
Full textAbstract:
Background:Since the 2015 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably.Objectives:The goal of the GRAPPA recommendations update is to develop high quality, evidence-based recommendations for the treatment of PsA, including related conditions and comorbidities.Methods:GRAPPA rheumatologists, dermatologists and patient research partners (PRPs) updated overarching principles for the management of adults with PsA by consensus. Principles considering use of biosimilars and tapering/discontinuing of therapy were added to this update. Systematic literature searches based on data publicly available from three databases (MEDLINE, EMBASE, and Cochrane CENTRAL) were conducted from the end of the previous recommendations’ searches through August 2020. Additional abstract searches were performed for conference presentations in 2017-2020. Searches covered PsA treatments (peripheral arthritis, axial arthritis, enthesitis, dactylitis, skin, and nail disease). Additional searches were performed for related conditions (uveitis and IBD) and comorbidities evaluating their impact on safety and treatment outcomes. Individual groups assessed the risk of bias and applied the GRADE system to generate strong or conditional recommendations for therapies within the domain groups and for the management of comorbidities and related conditions. These recommendations were then incorporated into an overall treatment schema.Results:Updated, evidence-based treatment recommendations are shown (Table 1). Since 2015, many new medications have been incorporated. Additional results for older medications, such as methotrexate, have been published across PsA domains. Based on the evidence, the treatment recommendations developed by individual groups were incorporated into the overall schema including principles for management of arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease in PsA, and associated conditions (Figure 1). Choice of therapy for an individual should ideally address all of the domains that impact on that patient, supporting shared decision making with the patient involved. Additional consideration in the recommendations was given to key associated conditions and comorbidities as these often impact on therapy choice.Conclusion:These GRAPPA treatment recommendations provide up to date, evidence-based guidance to providers who manage and treat adult patients with PsA. These recommendations are based on domain-based strategy for PsA and supplemented by overarching principles developed by consensus of GRAPPA members.IndicationStrongForConditional ForConditionalAgainstStrongAgainstInsufficient evidencePeripheral Arthritis DMARD NaïvecsDMARDs, TNFi, PDE4i, IL-12/23i, IL-17i, IL-23i, JAKiNSAIDs, oral CS, IA CS,IL-6i,Peripheral Arthritis DMARD IRTNFi, IL-12/23i, IL-17i, IL-23i, JAKiPDE4i, other csDMARD, NSAIDs, oral CS, IA CS,IL-6i,Peripheral ArthritisbDMARD IRTNFi, IL-17i, IL-23i, JAKi,NSAIDs, oral CS, IA CS, IL-12/23i, PDE4i, CTLA-4-IgIL-6i,Axial arthritis, Biologic NaïveNSAIDs, Physiotherapy, simple analgesia, TNFi, IL-17i, JAKiCS SIJ injections, bisphosphonatescsDMARDs, IL-6i,IL-12/23i, IL-23iAxial PsA, Biologic IRNSAIDs, Physiotherapy, simple analgesia, TNFi, IL-17i, JAKi csDMARDs, IL-6i,IL-12/23i, IL-23iEnthesitisTNFi, IL-12/23i, IL-17i, PDE4i, IL-23i, JAKiNSAIDs, physiotherapy, CS injections, MTXIL-6i,Other csDMARDsDactylitisTNFi IL-12/23i, IL-17i, IL-23i, JAKi, PDE4iNSAIDs, CS injections, MTXOther csDMARDsPsoriasisTopicals, phototherapy, csDMARDs, TNFi, IL-12/23i, IL-17i, IL-23i, PDE4i, JAKi AcitretinNail psoriasisTNFi, IL12/23i, IL17i, IL23i, PDE4iTopical CS, tacrolimus and calcipotriol combination or individual therapies, Pulsed dye laser, csDMARDs, acitretin, JAKiTopical Cyclosporine / Tazarotene, Fumarate, Fumaric Acid Esters, UVA and UVB Phototherapy, AlitretinoinIBDTNFi (not ETN), IL-12/23i, JAKiIL-17iUveitisTNFi (not ETN)Disclosure of Interests:Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, and Novartis, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb,GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb,GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Grant/research support from: AbbVie, Janssen, Novartis Pharma, Pfizer, Roche, and UCB, Nadia Corp: None declared, Heidi Bertheussen Consultant of: Pfizer, Kristina Callis-Duffin Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Lilly, Janssen, Novartis, Pfizer, Sienna Biopharmaceuticals, Stiefel Laboratories, UCB, Ortho Dermatologics, Inc, Regeneron Pharmaceuticals, Inc., Anaptys Bio, Boehringer Ingelheim., Cristiano Barbosa Campanholo Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Jeffrey Chau: None declared, Lihi Eder Consultant of: Abbvie, UCB, Janssen, Eli Lily, Pfizer, Novartis, Grant/research support from: Abbvie, UCB, Janssen, Eli Lily, Pfizer, Novartis, Daniel Fernandez Consultant of: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, Grant/research support from: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, Oliver FitzGerald Speakers bureau: AbbVie, Janssen and Pfizer Inc, Consultant of: BMS, Celgene, Eli Lilly, Janssen and Pfizer Inc, Grant/research support from: AbbVie, BMS, Eli Lilly, Novartis and Pfizer Inc, Amit Garg Consultant of: Abbvie, Amgen, Asana Biosciences, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, InflaRx, Janssen, Pfizer, UCB, Viela Biosciences, Grant/research support from: Abbvie, Dafna D Gladman Consultant of: Abbvie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Jansen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, Eli Lilly, Jansen, Novartis, Pfizer and UCB, Niti Goel: None declared, Suzanne Grieb: None declared, Philip Helliwell Speakers bureau: Janssen, Novartis, Pfizer, Consultant of: Eli Lilly, M Elaine Husni Consultant of: Abbvie, Amgen, Janssen, Novartis, Lilly, UCB, Regeneron, and Pfizer, Deepak Jadon Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Arnon Katz: None declared, Dhruvkumar Laheru: None declared, John Latella: None declared, Ying Ying Leung Speakers bureau: Novartis, AbbVie, Eli Lilly, Janssen, Consultant of: Pfizer and Boehringer Ingelheim, Grant/research support from: Pfizer and conference support from AbbVie, Christine Lindsay Shareholder of: Amgen, Employee of: Aurinia pharmaceuticals, Ennio Lubrano Speakers bureau: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Consultant of: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Luis Mazzuoccolo Speakers bureau: Abbvie, Amgen, Novartis, Elli Lilly, Jansen, Consultant of: Abbvie, Amgen, Novartis, Elli Lilly, Jansen, Roland McDonald: None declared, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer, SUN and UCB, Denis O’Sullivan: None declared, Alexis Ogdie Consultant of: AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, and Pfizer, Grant/research support from: Novartis and Pfizer and Amgen, Wendy Olsder: None declared, Lori Schick: None declared, Ingrid Steinkoenig: None declared, Maarten de Wit Consultant of: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche, Danielle van der Windt: None declared, Arthur Kavanaugh Speakers bureau: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB
26
Hasanah, Eny Nur, Wahono Wahono, and Tri Kurniawati. "Pengaruh Sandal Bakiak Terhadap Keterampilan Sosial Anak Di Tk S Melati Surabaya." Pedagogi : Jurnal Anak Usia Dini dan Pendidikan Anak Usia Dini 5, no. 1 (July 20, 2019): 90. http://dx.doi.org/10.30651/pedagogi.v5i1.2799.
Full textAbstract:
Abstrak: Permainan sandal bakiak merupakan jenis permainan berkelompok, sehingga anak dapat memperlihatkan penampakan aspek-aspek sosial yang berhubungan dengan kemampuan anak dalam suatu keterampilan sosial. Penelitian ini bertujuan untuk mengetahui pengaruh sandal bakiak terhadap keterampilan sosial anak. Metodologi penelitian menggunakan jenis penelitian kuantitatif dengan desain one group pretest posttest karena hanya menggunakan satu kelas sebagai sampel penelitian dan adanya tahapan pretest, posttest sebagai proses pemerolehan data. Teknik analisis data menggunakan uji Wilcoxon yang memiliki kriteria jika T hitung < T tabel maka Ha diterima. Hasil analisis data memperoleh nilai T hitung 0 dan nilai T tabel 40, karena 0<40 maka hasil penelitian meyatakan bahwa terdapat pengaruh permainan sandal bakiak terhadap keterampilan sosial anak.Kata kunci: Sandal Bakiak; Keterampilan Soial; Anak Usia Dini.Abstract: Clogs games are a type of group game, so children can show the appearance of social aspects that are related to children's abilities in a social skill. This study aims to determine the effect of clogs on children's social skills. The research methodology uses a quantitative type of research with the design of one group pretest posttest because it only uses one class as a research sample and the pretest stage, posttest as the process of obtaining data. The data analysis technique uses the Wilcoxon test which has criteria if T count <T table then Ha is accepted. The results of the data analysis obtained a T value of 0 and a value of T table 40, because 0 <40 then the results of the study stated that there was an influence of clogs playing on children's social skills.Keywords: Clogs Sandals; Skills; Early childhood.
27
Bransby, M. F., and S. M. Springman. "Centrifuge Modelling of Pile Groups Adjacent to Surcharge Loads." Soils and Foundations 37, no. 2 (June 1997): 39–49. http://dx.doi.org/10.3208/sandf.37.2_39.
Full text
28
Chen, L. T., H. G. Poulos, and T. S. Hull. "Model Tests on Pile Groups Subjected to Lateral Soil Movement." Soils and Foundations 37, no. 1 (March 1997): 1–12. http://dx.doi.org/10.3208/sandf.37.1.
Full text
29
Shanker, K., P. K. Basudhar, and N. R. Patra. "Uplift Capacity of Pile Groups Embedded in Sands: Predictions and Performance." Soils and Foundations 46, no. 5 (October 2006): 605–12. http://dx.doi.org/10.3208/sandf.46.605.
Full text
30
Bouassida, M., and A. Porbaha. "Ultimate Bearing Capacity of Soft Clays Reinforced by a Group of Columns—Application to a Deep Mixing Technique." Soils and Foundations 44, no. 3 (June 2004): 91–101. http://dx.doi.org/10.3208/sandf.44.3_91.
Full text
31
Pasaribu, Luxi Riajuni, and Lely Indrawati. "DETERMINAN KULTURAL DAN STRUKTURAL DALAM KEMITRAAN BIDAN DENGAN DUKUN BAYI (BHISA/SANDO) DI KABUPATEN WAKATOBI, SULAWESI TENGGARA." Jurnal Kesehatan Reproduksi 12, no. 1 (August 30, 2021): 89–101. http://dx.doi.org/10.22435/kespro.v12i1.4013.
Full textAbstract:
Abstract
Background: Births assisted by skilled health personnel in health facilities is the prevention of maternal mortality. Wakatobi District has a low coverage of birth attendance by skilled health personnel, and the community has a powerful culture in all aspects of life, including visiting traditional birth attendants known as Bhisa/Sando in caring for women from pregnant to childbirth.
Objective: To identify the cultural and structural determinants that affect the partnership between Bhisa/Shando and midwives in maternal and child health services (MCH).
Methods: This study used an operational research design with a qualitative approach. A total of 68 informants were involved in focus group discussions, in-depth interviews, and participatory observations. Thematic analysis was used in processing all information.
Results: Cultural determinants that affect the partnership between Bhisa/Shando and midwives were hereditary traditions and a powerful belief in Bhisa/Shando's ability to take care for pregnant women, labor women, postpartum women, and newborns. Meanwhile, structural determinants included inadequate facilities and health personnel for MCH services and suboptimal supports from related parties. These results may cause the partnership between Bhisa/Shando and midwives will not be optimal.
Conclusion: Cultural and structural factors have a strong influence in realizing the partnership between Bhisa/Sando and midwives. The involvement of Bhisa/Sando in MCH services conducted by midwives, adequate MCH service infrastructure, and support from community leaders, cadres, and related agencies is essential to be carried out to improve Bhisa/Sando's partnership with midwives in improving MCH services.
Keywords: Bhisa/Shando, partnership of midwives and traditional birth attendants, maternal and child health
Abstrak
Latar belakang: Persalinan yang ditolong oleh tenaga kesehatan di fasilitas kesehatan merupakan upaya untuk mencegah kematian ibu. Kabupaten Wakatobi memiliki cakupan penolong persalinan oleh tenaga kesehatan yang rendah, dan masyarakatnya memiliki budaya yang sangat kuat dalam segala aspek kehidupan, termasuk mendatangi dukun bayi yang disebut sebagai Bhisa/Sando dalam menangani ibu hamil hingga bersalin.
Tujuan: Mengidentifikasi determinan kultural dan struktural yang memengaruhi kemitraan antara Bhisa/Shando dengan bidan dalam pelayanan kesehatan ibu dan anak (KIA).
Metode: Studi ini menggunakan desain riset operasional dengan pendekatan kualitatif. Total 68 informan terlibat dalam diskusi grup terarah, wawancara mendalam, dan observasi partisipasi. Analisis tematik digunakan dalam mengolah seluruh informasi.
Hasil: Determinan kultural yang memengaruhi kemitraan antara Bhisa/Shando dengan bidan yaitu tradisi turun temurun dan kepercayaan yang kuat terhadap kemampuan Bhisa/Shando dalam menangani ibu hamil, ibu bersalin, ibu nifas, dan bayi baru lahir. Sedangkan determinan struktural meliputi fasilitas dan tenaga kesehatan untuk pelayanan KIA yang belum memadai serta dukungan dari pihak terkait yang belum optimal. Hal ini menyebabkan kemitraan antara Bhisa/Shando dengan bidan belum optimal.
Kesimpulan: faktor kulturan dan struktural berpengaruh kuat dalam mewujudkan kemitraan antara Bhisa/Sando dengan bidan. Keterlibatan Bhisa/Sando dalam pelayanan KIA yang dilakukan bidan, infrastruktur pelayanan KIA yang memadai, dan dukungan dari tokoh masyarakat, kader, dan instansi terkait perlu dilakukan untuk meningkatkan kemitraan Bhisa/Sando dengan bidan dalam meningkatkan pelayanan KIA.
Kesimpulan: Kualitas hidup ibu hamil dan ibu nifas relatif sama dengan kecenderungan lebih rendah pada kualitas hidup ibu nifas
Kata kunci: Bhisa/Shando, kemitraan bidan dan dukun bayi, kesehatan ibu dan anak
32
Dunbar, Lindsay, and Mike Roy. "A Viking-age inhumation from Crow Taing, Sanday, Orkney." Scottish Archaeological Journal 40, no. 1 (March 2018): 83–99. http://dx.doi.org/10.3366/saj.2018.0095.
Full textAbstract:
The islands of Orkney have long been associated with examples of Viking-age activity and often yield unique and well preserved records from the Viking and Late Norse periods. Investigations on the island of Sanday in Orkney, as part of a call off contract for human remains between Historic Environment Scotland and AOC Archaeology Group, have revealed the presence of an inhumation in association with an iron knife. Further investigation reveals that the burial is that of an adolescent skeleton (12–17 years). The north-east/south-west alignment of the body, in a flexed position, and its association with an iron knife indicates a pre-Christian burial rite, in line with a 9th or 10th century AD date, which corresponds with radiocarbon dating carried out on the skeletal remains. This burial contributes a new record to the wealth of evidence from around this period within the surrounding landscape on the island of Sanday.
33
Choquette, D., L. Bessette, L. Choquette Sauvageau, I. Ferdinand, B. Haraoui, F. Massicotte, J. P. Pelletier, et al. "AB0337 TOFACITINIB MONOTHERAPY OR COMBINED WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS SHOW SIMILAR RETENTION OVER FOUR YEARS. REPORT FROM RHUMADATA ®." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1467.1–1467. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2479.
Full textAbstract:
Background:Since the introduction of biologic agents around the turn of the century, the scientific evidence shows that the majority of agents, independent of the therapeutic target, have a better outcome when used in combination with methotrexate (MTX). In 2014, tofacitinib (TOFA), an agent targeting Janus kinase 1 and 3, has reached the Canadian market with data showing that the combination with MTX may not be necessary [1,2].Objectives:To evaluate the efficacy and retention rate of TOFA in real-world patients with rheumatoid arthritis (RA).Methods:Two cohorts of patients prescribed TOFA was created. The first cohort was formed of patients who were receiving MTX concomitantly with TOFA (COMBO) and the other of patients using TOFA in monotherapy (MONO). MONO patients either never use MTX or were prescribed MTX post-TOFA initiation for at most 20% of the time they were on TOFA. COMBO patients received MTX at the time of TOFA initiation or were prescribed MTX post-TOFA initiation for at least 80% of the time. For all those patients, baseline demographic data definitions. Disease activity score and HAQ-DI were compared from the initiation of TOFA to the last visit. Time to medication discontinuation was extracted, and survival was estimated using Kaplan-Meier calculation for MONO and COMBO cohorts.Results:Overall, 194 patients were selected. Most were women (83%) on average younger than the men (men: 62.6 ± 11.0 years vs. women: 56.9 ± 12.1 years, p-value=0.0130). The patient’s assessments of global disease activity, pain and fatigue were respectively 5.0 ± 2.7, 5.2 ± 2.9, 5.1 ± 3.1 in the COMBO group and 6.2 ± 2.5, 6.5 ± 2.6, 6.3 ± 2.8 in the MONO group all differences being significant across groups. HAQ-DI at treatment initiation was 1.3 ± 0.7 and 1.5 ± 0.7 in the COMBO and MONO groups, respectively, p-value=0.0858. Similarly, the SDAI score at treatment initiation was 23.9 ± 9.4 and 25.2 ± 11.5, p-value=0.5546. Average changes in SDAI were -13.4 ± 15.5 (COMBO) and -8.9 ± 13.5 (MONO), p-value=0.1515, and changes in HAQ -0.21 ± 0.63 and -0.26 ± 0.74, p-value 0.6112. At treatment initiation, DAS28(4)ESR were 4.4 ± 1.4 (COMBO) and 4.6 ± 1.3 (MONO), p-value 0.5815, with respective average changes of -1.06 ± 2.07 and -0.70 ± 1.96, p-value=0.2852. The Kaplan-Meier analysis demonstrated that the COMBO and MONO retention curves were not statistically different (log-rank p-value=0.9318).Conclusion:Sustainability of TOFA in MONO or COMBO are not statistically different as are the changes in DAS28(4)ESR and SDAI. Despite this result, some patients may still benefit from combination with MTX.References:[1]Product Monograph - XELJANZ ® (tofacitinib) tablets for oral administration Initial U.S. Approval: 2012.[2] Reed GW, Gerber RA, Shan Y, et al. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis [published online ahead of print, 2019 Nov 9].Rheumatol Ther. 2019;6(4):573–586. doi:10.1007/s40744-019-00177-4.Disclosure of Interests:Denis Choquette Grant/research support from: Rhumadata is supported by grants from Pfizer, Amgen, Abbvie, Gylead, BMS, Novartis, Sandoz, eli Lilly,, Consultant of: Pfizer, Amgen, Abbvie, Gylead, BMS, Novartis, Sandoz, eli Lilly,, Speakers bureau: Pfizer, Amgen, Abbvie, Gylead, BMS, Novartis, Sandoz, eli Lilly,, Louis Bessette Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, UCB Pharma, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, UCB Pharma, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Sanofi, Loïc Choquette Sauvageau: None declared, Isabelle Ferdinand Consultant of: Pfizer, Abbvie, Amgen, Novartis, Speakers bureau: Pfizer, Amgen, Boulos Haraoui Grant/research support from: Abbvie, Amgen, Pfizer, UCB, Grant/research support from: AbbVie, Amgen, BMS, Janssen, Pfizer, Roche, and UCB, Consultant of: Abbvie, Amgen, Lilly, Pfizer, Sandoz, UCB, Consultant of: AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Merck, Pfizer, Roche, and UCB, Speakers bureau: Pfizer, Speakers bureau: Amgen, BMS, Janssen, Pfizer, and UCB, Frédéric Massicotte Consultant of: Abbvie, Janssen, Lilly, Pfizer, Speakers bureau: Janssen, Jean-Pierre Pelletier Shareholder of: ArthroLab Inc., Grant/research support from: TRB Chemedica, Speakers bureau: TRB Chemedica and Mylan, Jean-Pierre Raynauld Consultant of: ArthroLab Inc., Marie-Anaïs Rémillard Consultant of: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Paid instructor for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Speakers bureau: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Diane Sauvageau: None declared, Édith Villeneuve Consultant of: Abbvie, Amgen, BMS, Celgene, Pfizer, Roche, Sanofi-Genzyme,UCB, Paid instructor for: Abbvie, Speakers bureau: AbbVie, BMS, Pfizer, Roche, Louis Coupal: None declared
34
Bessette, L., B. Florica, P. A. Fournier, T. Girard, L. Naik, D. Sholter, and P. Baer. "POS0288 A CANADIAN RETROSPECTIVE CHART REVIEW EVALUATING CONCOMITANT METHOTREXATE DE-ESCALATION PATTERNS IN RA PATIENTS TREATED WITH BIOLOGIC OR TARGETED SYNTHETIC DMARDS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 388.1–389. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1286.
Full textAbstract:
BackgroundRheumatoid arthritis (RA) guidelines recommend methotrexate (MTX) as anchor therapy in combination with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). However, its tolerability is challenging with a significant proportion of patients not adhering to their prescribed MTX regimen following b/tsDMARD initiation. Rates of MTX tapering and withdrawal have been reported elsewhere but Canadian data are lacking.ObjectivesThis multi-centre, retrospective chart-based cohort study assessed the frequency of MTX withdrawal or tapering following initiation of a b/tsDMARD in Canadian adults with RA.MethodsPatients were eligible if they received MTX for ≥3 months before initiation of a b/tsDMARD that was then prescribed continuously for ≥18 months and was initiated in combination with MTX. Patients taking oral prednisone or equivalent at a dose >10 mg per day, and those whose b/tsDMARD was prescribed prior to 2014, were excluded.ResultsData from 889 patients were included in the analysis. Mean age was 50.6 years and 72.6% were female. Mean time since diagnosis was approximately 8 years. Of the 46.1% of patients with a documented assessment of disease status at baseline, 62.7% of patients had high disease activity. Baseline mean (SD) MTX dose was 18.9 (6.63) mg/week, administered orally (57.4%), subcutaneously (41.3%), or intramuscularly (1.2%). Overall, 270 (30.4%) patients either tapered (123, 13.8%) or discontinued (147, 16.5%) their MTX within 2 years of initiating the b/tsDMARD. Methotrexate dose was unchanged for 582 (65.5%) subjects and increased for 37 (4.2%) subjects. The prescribed b/tsDMARD was most often a tumor necrosis factor inhibitor (TNFi,52.1%), followed by a Janus kinase inhibitor (JAKi, 18.3%), other modes of action (OMA) which included abatacept and rituximab (17.7%) and interleukin-6 inhibitor (IL-6i, 11.9%). The b/tsDMARD type with the highest frequency of MTX Taper or Discontinued was IL-6i (37 patients, 34.9%) followed by TNFi (144 patients, 31.1%), JAKi (47 patients, 28.8%) and OMA (44 patients, 28.0%). In the MTX Discontinued group, the most common reasons for MTX discontinuation were patient decision (27.2%) and adverse events (24.5%). In the MTX Tapered group, the most common reasons for MTX dose change were planned tapering (36.6%) and adverse events (29.3%). In the MTX Increased group, insufficient clinical response (73.0%) was the most common reason provided for MTX dose change. Baseline factors associated with MTX dose discontinuation and tapering by multiple logistic regression were a shorter time since diagnosis (Odds ratio [OR]: 0.981; 95% confidence interval [CI]: 0.964 – 0.999. P=0.0401), use of non-DMARD medications excluding steroids (OR: 0.683; 95%CI: 0.503 – 0.929. P=0.0150) and a greater number of comorbidities (OR: 1.054; 95%CI: 1.001 – 1.110. P=0.0444). The mean (SD) weekly MTX dose at the end of the data extraction period was 14.13 (4.81) mg for the MTX Tapered group, with 109 (88.6%) subjects taking a weekly MTX dose ≥10 mg. In the MTX Increased group the mean (SD) weekly MTX dose was 22.3 (3.74) mg. Interpretation of the effect of MTX dose on disease activity, fatigue, pain and functional status is challenging due to missing data, but most patients in all 4 groups transitioned to low disease activity or remission during the study period.ConclusionMethotrexate withdrawal or tapering occurred in 30.4% of Canadians with RA within two years following b/tsDMARD initiation. There was no evidence of worsening disease activity in these patients. These proportion of Canadian RA patients who reduce or discontinue MTX after the initiation of a ts/bDMARD are generally consistent with those reported in other regions of the world.AcknowledgementsAbbVie Corp. funded the research for this study and provided writing support for this abstract. AbbVie participated in the study design; study research; collection, analysis, and interpretation of data; and writing, reviewing, and approving this abstract for submission. All authors had access to the data; participated in the development, review, and approval of the abstract; and agreed to submit this abstract to EULAR 2022.AbbVie and the authors thank all study investigators for their contributions and the patients who participated in this study. Medical writing support was provided by John Howell PhD of McDougall Scientific and funded by AbbVie, Inc.Disclosure of InterestsLouis Bessette Speakers bureau: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Lilly, Novartis, Sanofi, Sandoz, Gilead, Fresenius Kabi, Consultant of: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Lilly, Novartis, Sanofi, Sandoz, Gilead, Fresenius Kabi, Grant/research support from: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Merck, Lilly, Novartis, Sanofi, Sandoz, Gilead, Fresenius Kabi, Brandusa Florica Speakers bureau: AbbVie, Amgen, Lilly, Pfizer, Janssen, Novartis, Merck, Consultant of: AbbVie, Amgen, Lilly, Pfizer, Janssen, Novartis, Merck, Grant/research support from: AbbVie, Amgen, Lilly, Pfizer, Janssen, Novartis, Merck, Pierre-André Fournier Shareholder of: AbbVie, Employee of: AbbVie, Tanya Girard Shareholder of: AbbVie, Employee of: AbbVie, Latha Naik Speakers bureau: AbbVie, Consultant of: AbbVie, Grant/research support from: AbbVie, Dalton Sholter Speakers bureau: AbbVie, Amgen, BMS, Celgene, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, UCB, Consultant of: AbbVie, Amgen, BMS, Celgene, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, UCB, Grant/research support from: AbbVie, Amgen, BMS, Celgene, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, UCB, Philip Baer Speakers bureau: Abbvie, Amgen, Lilly, Pfizer, Janssen, Teva, Fresenius Kabi, Viatris, Opticann, Novartis, Organon, Gilead, Celltrion, Astra Zeneca, GSK, Consultant of: Abbvie, Amgen, Lilly, Pfizer, Janssen, Teva, Fresenius Kabi, Viatris, Opticann, Novartis, Organon, Gilead, Celltrion, Astra Zeneca, GSK, Grant/research support from: Abbvie, Amgen, Lilly, Pfizer, Janssen, Teva, Fresenius Kabi, Viatris, Opticann, Novartis, Organon, Gilead, Celltrion, Astra Zeneca, GSK
35
Comodromos, Emilios M. "Response Evaluation of Axially Loaded Fixed Head Pile Groups Using 3D Nonlinear Analysis." Soils and Foundations 44, no. 2 (April 2004): 31–39. http://dx.doi.org/10.3208/sandf.44.2_31.
Full text
36
Imamura, Shinichiro, Toshiyuki Hagiwara, Yoshimichi Tsukamoto, and Kenji Ishihara. "Response of Pile Groups Against Seismically Induced Lateral Flow in Centrifuge Model Tests." Soils and Foundations 44, no. 3 (June 2004): 39–55. http://dx.doi.org/10.3208/sandf.44.3_39.
Full text
37
Meyer-Olson, D., K. Hoeper, L. Hammel, S. Lieb, A. Haehle, and U. Kiltz. "AB0785 Role of Patient Organizations in Implementation of Recommended Non-pharmacological Treatment Modalities in Spondyloarthritis: Evidence for the Effectiveness of Self-management Strategies." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1519. http://dx.doi.org/10.1136/annrheumdis-2022-eular.815.
Full textAbstract:
BackgroundEULAR recommends participation in patient (pt) organizations to improve pt self-management of axial spondyloarthritis (axSpA)1. Non-pharmacological treatment modalities (NPTM)2 are recommended in axSpA treatment guidelines.3ObjectivesTo characterize the impact of pt advocacy group membership and its association with NPTM frequency and clinical parameters in axSpA.MethodsPts with a confirmed axSpA diagnosis were enrolled in the multicenter, observational ATTENTUS-axSpA survey conducted across Germany (11/2019–07/2020). Demographics, clinical and pt-related data were collected electronically.ResultsOf the 787 enrolled axSpA pts, this analysis was conducted on the working population (n=695)4. Overall, 12.2% (n=85) pts were members of a pt advocacy group and 87.8% (n=610) were not. Pt advocacy group members had higher Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, increased functional impairment (BASFI, Bath Ankylosing Spondylitis Functional Index) and higher impact of axSpA on health (ASAS-HI, Assessment of SpondyloArthritis International Society-Health Index; Table 1). Despite worse prognostic factors, there was no significant difference in Work Productivity and Activity Impairment (WPAI) score [40.6 (27.0) for pt advocacy group members vs 36.8 (29.9) for non-members; p=0.380]. Membership in a pt advocacy group was associated with increased prescribed, supervised NPTM (57.6% [n=49] vs 34.4% [n=210]). Pts reported to have ever received 2.6 rehabilitation measures, and ≥3.0 different rehabilitation NPTM measures. Cumulatively, 25.0% (N=654) of rehabilitation measures were physiotherapy (Figure 1).Table 1.Descriptive characteristics and impact of membership in pt advocacy groupCharacteristicPatient advocacy group member (n=85)Not patient advocacy group member (n=610)Total (n=695)p-valueAge (yrs), mean (SD)50.2 (7.7)44.6 (11.1)45.3 (10.9)<0.001BMI (kg/m2) mean (SD)27.5 (5.0)28.0 (12.7)28.0 (12.0)0.713Male, n (%)45 (52.9)378 (62.0)423 (60.9)0.128Disease duration (yrs) mean (SD)13.7 (10.3)12.5 (11.1)12.6 (11.0)0.303ASAS-HI, 0-177.3 (3.4)6.4 (3.9)6.5 (3.8)0.045BASDAI, 0-104.3 (1.9)3.8 (2.2)3.9 (2.2)0.044BASDAI ≥4, n (%)49 (57.6)275 (45.1)324 (46.6)0.025BASFI, 0-103.9 (2.3)3.2 (2.5)3.3 (2.4)0.015Biologic treatment, n (%)52 (61.2)312 (51.1)364 (52.4)0.072Full time employment, n (%)48 (56.5)410 (67.2)458 (65.9)0.06Absenteeism*, mean (SD)8.4 (21.2)10.9 (26.8)10.6 (26.2)-Presenteeism*, mean (SD)38.4 (24.6)31.8 (25.7)32.6 (25.6)-Overall work impairment score*, mean (SD)40.6 (27.0)36.8 (29.9)37.2 (29.6)0.380Activity impairment, mean (SD)46.7 (21.7)40.5 (26.8)41.3 (26.4)0.058Pts having ever received medicinal rehabilitation measures, mean (SD)67 (78.8)328 (53.8)395 (56.8)<0.001Prescribed supervised group NPTM#, mean (SD)49 (57.6)210 (34.4)259 (37.3)<0.001Regular physical training†, mean (SD)76 (89.4)515 (84.4)591 (85.0)0.231*Work-related questions of WPAI-score have been calculated for pts in employment (N=340); †regular physical training in the context of axSpA; #rehabilitation sport and/or functional training. ASAS-HI, Assessment of SpondyloArthritis International Society-Health Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, Body Mass Index; n, number of pts; pts, patients; SD, Standard Deviation; WPAI, Work Productivity and Activity Impairment; yrs, years.ConclusionPt advocacy group membership was associated with increased prescribed NPTM in axSpA. Pt organizations may support the implementation of guidelines and improvement of self-management strategies in pts with axSpA, which may influence work participation.References[1]Nikiphorou E, et al. Ann Rheum Dis 2021;0:1–8[2]Rausch Osthoff A-K, et al. Ann Rheum Dis 2018;77:1251–1260[3]van der Heijde D, et al. Ann Rheum Dis 2017;76:978–991[4]Kiltz et al. 2021. EULAR eposter; POS0983Disclosure of InterestsDirk Meyer-Olson Speakers bureau: Speakers bureau: Abbvie, Amgen,Berlin Chemie, Bristol Myers Squibb, Cellgene, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Novartis, Pfizer, Sandoz Hexal, Sanofi and UCB, Consultant of:Abbvie, Amgen, Berlin Chemie, Bristol Myers Squibb, Cellgene, Chugai, Fresenius Kabi, GSK, Jansen Cilag, Lilly, Medac, Merck Sharp & Dome, Mylan, Novartis, Pfizer, Sandoz Hexal, Sanofi and UCB, Kirsten Hoeper Speakers bureau: Speakers bureau: Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal and Sanofi., Consultant of: Abbvie, Chugai, Gilead, Lilly, Novartis, Sandoz Hexal and Sanofi., Ludwig Hammel: None declared, Sebastian Lieb Employee of: Employee of Novartis, Andreas Haehle Employee of: Employee of Novartis, Uta Kiltz Speakers bureau: Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: Abbvie, Amgen, Biogen, Fresenius, GSK, Novartis and Pfizer
38
Khukhlina, O. S., O. Ye Hryniuk, and A. A. Antoniv. "OXIDATIVE STRESS INTENSITY AND STATE OF SEPARATE ANTIOXIDANT PROTECTION FACTORS IN ANTRALE TREATMENT IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS, OBESITY, AND CHRONIC OBSTRUCTIVE LUNG DISEASE." Eastern Ukrainian Medical Journal 8, no. 2 (2020): 129–36. http://dx.doi.org/10.21272/eumj.2020;8(2):129-136.
Full textAbstract:
The aim of the research was to assess the effectiveness of Antral regarding the impact on the intensity of lipid peroxidation, antioxidant system factors in NASH patients against the background of obesity and comorbidity with COPD. Material and methods of research: 76 NASH patients with class I obesity of and COPD 2-3 D were examined: 23 patients (group 1 – control group) received basic NASH therapy (Esentsiale forte N (Sanofi Avensis/Gutterman and Cie GmbH) 300 mg, 2 caps., 3 times per day) for 30 days and COPD therapy (Symbicort Turbuhaler (budesonide 160 mg/d + formoterol fumarate 4,5 mg/s) (AstraZeneca AB, Sweden) inhaled 2 times per day for 30 days, Berodual (ipratropium/fenoterol (250/500 mg/ml) (Institute de Angele Italy/Boehringer Ingelheim International GmbH) nebulizer inhalation 2 times per day, azithromycin (Azithro Sandoz, Ukraine Sandoz) 500 mg, 1 time per day for 10 days). The second group (basic group, B1) consisted of 25 NASH patients with class I obesity and COPD 2-3 D, in addition to the same basic COPD therapy, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day for 60 days as a hepatoprotection. The third group (basic group, B2) included 28 NASH patients with class I obesity and COPD 2-3 D, except the same basic COPD treatment, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day as a hepatoprotection, and Phytostatin (Polyconazole) (OmniFarma LLC, Ukraine) 20 mg after dinner for 30 days. Research results. In NASH patients against the background of obesity and COPD, a significant intensity of oxidative stress has been established with an increase in the blood of intermediate and final products of lipid peroxidation content (in 1.7–2.2 times, p < 0.05) against the background of a significant deficit in the restored glutathione in the blood (in 1.6 times, p < 0.05), which was accompanied by a compensatory voltage of catalase activity (increases in 1.7 times, p < 0.05). Conclusion. The combined prescription of Antral for 30 days led to a significant correction of oxidative-antioxidant homeostasis in NASH patients against the background of obesity and COPD with a probable decrease of malonic aldehyde, isolated double bonds, conjugated dienes (p < 0.05), a probable increase the reduced glutathione content in red blood cells (p < 0.05).
39
Motamed, Ramin, Ikuo Towhata, Tsuyoshi Honda, Susumu Yasuda, Kentaro Tabata, and Hiroshi Nakazawa. "Behaviour of Pile Group behind a Sheet Pile Quay Wall Subjected to Liquefaction-Induced Large Ground Deformation Observed in Shaking Test in E-Defense Project." Soils and Foundations 49, no. 3 (June 2009): 459–75. http://dx.doi.org/10.3208/sandf.49.459.
Full text
40
Costa, Ana Rafaella Araújo, Hugo Jário de Almeida Silva, André Augusto Martines Teixeira Mendes, Rodrigo Scattone Silva, Caio Alano de Almeida Lins, and Marcelo Cardoso de Souza. "Effects of insoles adapted in flip-flop sandals in people with plantar fasciopathy: a randomized, double-blind clinical, controlled study." Clinical Rehabilitation 34, no. 3 (December 6, 2019): 334–44. http://dx.doi.org/10.1177/0269215519893104.
Full textAbstract:
Objective: To evaluate the effects of insoles adapted into flip-flop sandals on pain and function in individuals with plantar fasciopathy (PF). Design: Randomized, double-blind controlled study. Setting: Physiotherapy clinic of the Faculty of Health Sciences of Trairi, Federal University of Rio Grande do Norte, Santa Cruz, Brazil. Subjects: Sixty-six patients of both genders with PF were randomized into two groups: sandal insole group (SI; n = 34), which received a pair of custom flip-flop sandals with insoles covered with smooth synthetic leather; and plain sandal group (PS; n = 32), which received an identical pair of flip-flop sandals, but without the insoles. Interventions: Patients were instructed to wear the flip-flops for 12 weeks for at least 4 hours/day. Main measures: Pain (visual analogue scale—VAS) in the morning and at the end of the day were considered primary outcomes. Function (Foot Function Index—FFI and Foot and Ankle Ability Measure—FAAM) and functional capacity (6-minute walk test—6MWT) were considered secondary outcomes. The outcomes were evaluated at baseline and immediately after the intervention by a blind assessor. Results: Between-group differences were observed in terms of morning pain (mean difference (MD) = –1.82 cm; 95% confidence interval (CI) = –3.3 to −0.3; P = 0.016) and function (MD = –0.10; 95% CI = –0.19 to −0.01; P = 0.023) after the interventions with the SI group showing superior improvements in comparison to the PS group. Conclusion: The use of insoles adapted in flip-flop sandals for 12 weeks was effective at improving pain and function in individuals with PF. Level of evidence: 1b.
41
Movahedi, M., D. Choquette, L. Coupal, A. Cesta, X. LI, E. Keystone, and C. Bombardier. "OP0179 DISCONTINUATION RATE OF TOFACITINIB IS SIMILAR WHEN COMPARED TO TNF INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 107–8. http://dx.doi.org/10.1136/annrheumdis-2021-eular.912.
Full textAbstract:
Background:Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease- modifying antirheumatic drugs (bDMARDs), including tumor necrosis factor inhibitors (TNFi). The similarity in retention of TNFi and TOFA was previously reported separately by the Ontario Best Practices Research Initiative (OBRI) and the Quebec cohort RHUMADATA®.Objectives:To increase the study power, we propose to evaluate the discontinuation rate (due to any reason) of TNFi compared to TOFA, using pooled data from both these registries.Methods:RA patients enrolled in the OBRI and RHUMADATA initiating their TOFA or TNFi between 1st June 2014 (TOFA approval date in Canada) and 31st Dec 2019 were included. Time to discontinuation was assessed using adjusted Kaplan-Meier (KM) survival and Cox regression models. To deal with confounding by indication, we estimated propensity scores for covariates with a standard difference greater than 0.1. Models were then adjusted using stratification and inverse probability of treatment weight (IPTW) methods. Multiple imputation (Imputation by Chained Equation method, N=20) was used to deal with missing data for covariates at treatment initiation.Results:A total of 1318 patients initiated TNFi (n=825) or TOFA (n=493) with mean (SD) disease duration of 8.9 (9.3) and 13.0 (10.1) years, respectively. In the TNFi group, 78.8% were female and mean age (SD) at treatment initiation was 57.6 (12.6) years. In the TOFA group, 84.6% were female and mean (SD) age at treatment initiation was 59.5 (11.5) years. The TNFi group was less likely to have prior biologic use (33.9%) than the TOFA group (66.9%). At treatment initiation, the mean (SD) CDAI was significantly (p<0.05) lower in the TNFi group [20.0 (11.7)] compared to the TOFA group [22.1(12.4)]. Physical function measured by HAQ-DI was also significantly lower (p<0.05) in the TNFi compared to the TOFA group (1.2 vs.1.3).Over a mean follow-up of 23.2 months, discontinuation was reported in 309 (37.5%) and 182 (36.9%) of all TNFi and TOFA patients, respectively. After adjusting for propensity score deciles across 20 imputed datasets, there was no significant difference in discontinuation between treatment groups (adjusted HRs: 0.96, 95% CI: 0.78-1.18; p=0.69). The results were similar for two propensity adjustment methods. Figure 1 shows IPTW adjusted KM survival curves comparing discontinuation rates in patients treated with TNFi and TOFA.Figure 1.Note: Propensity Score Weighted (IPTW) Survival Curves was performed using one imputed datasetConclusion:In this pooled real -world data study, we found that TNFi and TOFA retention is similar in patients with RA. In the next step we will analysis the data for specific reasons of dicontinutaion. We will also repeat analysis comparing discontinuation in the first users versus those after one or more biologic failure.Disclosure of Interests:Mohammad Movahedi: None declared, Denis Choquette Grant/research support from: Rhumadata® is supported by unrestricted grants from Abbvie Canada, Amgen Canada, Eli Lilly Canada, Novartis Canada, Pfizer Canada, Sandoz Canada and Sanofi Canada., Louis Coupal: None declared, Angela Cesta: None declared, Xiuying Li: None declared, Edward Keystone Grant/research support from: Amgen, Merck, Pfizer Pharmaceuticals, PuraPharm. Speaker Honoraria Agreements: AbbVie, Amgen, Bristol-Myers Squibb Company, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepsis. Consulting Agreements/Advisory Board Membership: AbbVie, Amgen, Bristol-Myers Squibb Company, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi-Genzyme, Samsung Bioepsis, Claire Bombardier Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Aurora, Bristol-Meyers Squibb, Celgene, Hospira, Janssen, Lilly, Medexus, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB.Dr. Bombardier held a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology
42
Kielsmeier-Cook, Joshua, Tatiana V. Danilova, Bernd Friebe, and Matthew N. Rouse. "Resistance to the Ug99 Race Group of Puccinia graminis f. sp. tritici in Wheat–Intra/intergeneric Hybrid Derivatives." Plant Disease 99, no. 10 (October 2015): 1317–25. http://dx.doi.org/10.1094/pdis-09-14-0922-re.
Full textAbstract:
New races of Puccinia graminis f. sp. tritici, the causal agent of stem rust, threaten global wheat production. In particular, races belonging to the Ug99 race group significantly contribute to yield loss in several African nations. Genetic resistance remains the most effective means of controlling this disease. A collection of 546 wheat–intra- and intergeneric hybrids developed by W. J. Sando (United States Department of Agriculture, Beltsville, MD) was screened with eight races of P. graminis f. sp. tritici, including races TTKSK, TTKST, TTTSK, TRTTF, TTTTF, TPMKC, RKQQC, and QTHJC. There were 152 accessions resistant to one or more races and 29 accessions resistant to TTKSK, TTKST, and TTTSK. Of these 29 accessions, 9 were resistant to all races, 14 had infection type patterns that were indistinguishable from cultivars possessing Sr9h and Sr42, 2 were indistinguishable from accessions with SrTmp, and 4 did not display resistant patterns of accessions with any known Sr gene. Three accessions (604981, 605286, and 611932) characterized cytogenetically were disomic substitution lines, each with a single Thinopyrum ponticum chromosome pair. One accession (606057) was a disomic substitution or addition line with two pairs of T. ponticum chromosomes. In total, seven accessions are postulated to contain novel stem rust resistance genes. This research indicates the value of extant collections of wheat–intergeneric hybrids as sources of disease resistance genes.
43
Gaujoux-Viala, C., E. Dernis, E. Senbel, H. Herman-Demars, A. Courbeyrette, and R. M. Flipo. "POS0698 CHANGES IN RA PATIENT PROFILE AT INITIATION OF FIRST TARGETED THERAPY OVER A FIVE-YEAR PERIOD: ANALYSIS OF THE STRATEGE 1 AND STRATEGE 2 STUDIES." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 628.2–629. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3719.
Full textAbstract:
BackgroundThe objective of the STRATEGE2 study (inclusion period: Feb. 2019-Dec. 2020) is to describe the therapeutic strategy in rheumatoid arthritis (RA) patients treated with methotrexate (MTX) for at least 3 months, not having received targeted biological (bDMARD) or synthetic (tsDMARD) therapy and who are candidates for initiation of first b/tsDMARD therapy due to RA activity.The STRATEGE1 study [1] (conducted between 2014 and 2015) described the therapeutic strategies introduced for RA patients with an inadequate response to MTX monotherapy.ObjectivesWe aim to compare the profiles of patients included in these two studies at first prescription of b/tsDMARD therapy, in order to evaluate changes in rheumatologist practices over this five-year period.MethodsSTRATEGE1 and 2 are two French multicentre, prospective, longitudinal, observational studies including patients with confirmed RA (ACR 1987 or ACR/EULAR 2010). Our aim is to compare baseline data. Only data from the sub-group of patients initiating b/tsDMARD therapy are presented for STRATEGE1. Qualitative variables are compared by Fisher’s exact test and quantitative variables by t-test.ResultsIn STRATEGE1 (2014-2015), 117 out of 854 patients initiated a b/tsDMARD therapy. In STRATEGE2 (2019-2020), 230 patients were included, with 180 in the analysis population.Table 1.At baseline (before b/tsDMARD initiation)STRATEGE1 (N=117)STRATEGE2 (N=180)pMean age (years)52.6 ±12.556.4 ±13.60.0158RA duration (years)6.5 ±7.15.6 ±7.2NSRadiological signs50.0%48.0%NSAverage MTX initiation (years)4.6 ±4.34.3 ±5.3NSMTX per os44.0%28.9%0.0088→ mean dosage (mg/week)16.2 ±3.616.0 ±4.1NSMTX subcutaneous52.6%70.6%0.003→ mean dosage (mg/week)18.5 ±3.219.9 ±3.9NS→ Patients self-administration53.8%75.8%0.0001Corticosteroid therapy53%50.6%NS→ mean dosage (mg/day)8.1 ±4.19.5 ±5.8NSMean DAS284.6 ± .14.3 ±1.20.0074Mean HAQ1.4 ±0.91.0 ±0.7<0.0001The baseline visits involved initiation of b/tsDMARD therapy with 100% vs. 88.9% bDMARD (anti-TNF: 78.8% vs. 58.3%; anti-IL6: 6.7% vs. 12.8%; CTLA4 Ig: 11.5% vs. 16.7%; anti-CD20: 2.9% vs. 1.1%) and 0% vs. 11.1% tsDMARD. Therapeutic decisions concerning MTX were (STRATEGE 1 vs STRATEGE 2): identical regimen maintained (pharmaceutical form + dosage): 69.2% vs. 76.1%; discontinuation: 4.3% vs. 2.2%; adjustment: 26.7% vs. 21.7% [with dose reduction: 18.2% vs. 93.5% and/or change in pharmaceutical form (p.o. to SC): 54.5% vs. 0%].Main reasons for adjusting treatment were (STRATEGE 1 vs STRATEGE 2): active RA: 86.1% vs. 77.8%; RA not in remission: 3.5% vs. 21.1%; exacerbation based on clinical/laboratory parameters: 42.6% vs. 10%.ConclusionOver the five-year period, these results suggest a change in practices for RA patients with an inadequate response to MTX and initiating their first targeted therapy: now with earlier recourse to first targeted therapy, for less active RA, and more pronounced investigation of remission.References[1]C. Gaujoux-Viala et al. MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE. Rheumatology 2021;0:1-11. doi:10.1093/rheumatologykeab274.AcknowledgementsThe authors wish to acknowledge RCTs for their contribution to the statistical analysis, the investigators, centres and patients.Disclosure of InterestsCécile Gaujoux-Viala Speakers bureau: AbbVie; Amgen; Boehringer Ingelheim, Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB., Consultant of: AbbVie; Amgen; Boehringer Ingelheim, Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB., Emmanuelle Dernis Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugaï Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugaï Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Eric Senbel Speakers bureau: Abbvie, Amgen, Biogen, Janssen, Lilly, MSD, Nordic Pharma, Pfizer Roche-Chugai and Sandoz, Sanofi., Consultant of: Abbvie, Amgen, Biogen, Janssen, Lilly, MSD, Nordic Pharma, Pfizer Roche-Chugai and Sandoz, Sanofi., Hélène Herman-Demars Employee of: Nordic Pharma France, Agnès Courbeyrette Employee of: Nordic Pharma France, René-Marc Flipo Speakers bureau: Abbvie, Bristol-Myers Squibb, Eli-Lilly, Janssen, Medac, MSD, Nordic-Pharma, Novartis, Pfizer, Roche-Chugaï, and Sanofi., Consultant of: Abbvie, Bristol-Myers Squibb, Eli-Lilly, Janssen, Medac, MSD, Nordic-Pharma, Novartis, Pfizer, Roche-Chugaï, and Sanofi.
44
Berenbaum, F., T. Schnitzer, A. Kivitz, L. Viktrup, A. Hickman, G. Pixton, M. Brown, I. Davignon, and C. West. "FRI0378 GENERAL SAFETY AND TOLERABILITY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS: A POOLED ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 786.1–786. http://dx.doi.org/10.1136/annrheumdis-2020-eular.268.
Full textAbstract:
Background:Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the treatment of signs and symptoms of osteoarthritis (OA).Objectives:To assess the safety and tolerability of subcutaneous (SC) tanezumab in patients with OA.Methods:Data were derived from 3 randomized placebo-controlled OA trials. SC treatment (every 8 weeks for 16–24 weeks with 8–24 week follow-up) included placebo, tanezumab 2.5 mg, tanezumab 2.5/5 mg (2.5 mg at day 1 and 5 mg at week 8), and tanezumab 5 mg. Overall treatment-emergent adverse events (TEAEs) and TEAEs of abnormal peripheral sensation were pooled from all 3 trials (placebo N = 586; tanezumab: 2.5 mg N = 602, 2.5/5 mg N = 219, 5 mg N = 347). Pre-specified TEAEs potentially associated with sympathetic neuropathy (anhidrosis, bradycardia, hypohidrosis, orthostatic hypotension, or syncope) and pre-specified joint events (primary osteonecrosis, rapidly progressive OA [RPOA] type 1 or type 2, subchondral insufficiency fracture, or pathological fracture; adjudicated by an independent committee of experts) were pooled from the 2 trials that included prospective evaluation of sympathetic and joint safety (placebo N = 514; tanezumab: 2.5 mg N = 528, 2.5/5 mg N = 219, 5 mg N = 284). TEAEs are presented for the treatment period; joint safety is presented for the full study (treatment plus follow up) period.Results:Patient demographics (80.7% white, 66.8% female, mean age ≈ 63 years) and clinical characteristics were similar across groups. TEAE rates were: placebo = 51.7%, tanezumab 2.5 mg = 52.3%, tanezumab 2.5/5 mg = 47.0%, and tanezumab 5 mg = 54.8%. Of TEAEs occurring in ≥2% of patients in any group, only oedema peripheral, joint stiffness, and paraesthesia had a higher incidence (95% confidence interval excluded 0) in any tanezumab group relative to placebo. Serious TEAE rates were: placebo = 1.5%, tanezumab 2.5 mg = 2.2%, tanezumab 2.5/5 mg = 1.4%, and tanezumab 5 mg = 2.6%. Rates of treatment and/or study discontinuation due to TEAEs were: placebo = 2.2%, tanezumab 2.5 mg = 1.8%, tanezumab 2.5/5 mg = 0.5%, and tanezumab 5 mg = 1.4%. Only arthralgia and OA led to discontinuation in >1 patient in any group. TEAEs of abnormal peripheral sensation rates were: placebo = 2.2%, tanezumab 2.5 mg = 5.1%, tanezumab 2.5/5 mg = 3.2%, and tanezumab 5 mg = 6.1%. Paraesthesia and hypoaesthesia were the most common events. Potential sympathetic neuropathy TEAE rates were: placebo = 0.8%, tanezumab 2.5 mg = 1.5%, tanezumab 2.5/5 mg = 0.5%, and tanezumab 5 mg = 2.8%; exposure-adjusted rates were not statistically different between any tanezumab group and placebo. Bradycardia and orthostatic hypotension were the most common events. No patient was considered to have a sympathetic neuropathy. TEAEs of abnormal peripheral sensation and potential sympathetic neuropathy were mostly mild and resolved. Joint safety event rates were statistically different for tanezumab 5mg (3.2%), but not 2.5mg (1.9%) or 2.5/5mg (0.5%), compared to placebo (0%). RPOA type-1 was the most common event. Total joint replacement rates were: placebo = 4.5%, tanezumab 2.5 mg = 5.9%, tanezumab 2.5/5 mg = 6.8%, and tanezumab 5 mg = 7.0%; rates were not statistically different between any tanezumab group and placebo.Conclusion:Tanezumab was generally safe and well tolerated in most patients, with rates of overall TEAEs and treatment/study discontinuations similar to placebo and no evidence of a sympathetic safety signal. TEAEs of abnormal peripheral sensation and joint safety events were infrequent but more common with tanezumab than placebo.Disclosure of Interests:Francis Berenbaum Grant/research support from: TRB Chemedica (through institution), MSD (through institution), Pfizer (through institution), Consultant of: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, 4P Pharma, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Thomas Schnitzer Consultant of: Pfizer, Lilly, AstraZeneca, GSK, Alan Kivitz Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim,,Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, Lars Viktrup Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Anne Hickman Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Glenn Pixton Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Mark Brown Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Isabelle Davignon Shareholder of: Pfizer, Employee of: Pfizer, Christine West Shareholder of: Pfizer Inc, Employee of: Pfizer Inc
45
Shirato, Masahiro, Yoshinori Nonomura, Jiro Fukui, and Shoichi Nakatani. "Large-Scale Shake Table Experiment and Numerical Simulation on the Nonlinear Behavior of Pile-Groups Subjected to Large-Scale Earthquakes." Soils and Foundations 48, no. 3 (June 2008): 375–96. http://dx.doi.org/10.3208/sandf.48.375.
Full text
46
Motamed, Ramin, Vlatko Sesov, Ikuo Towhata, and Ngo Tuan Anh. "Experimental Modeling of Large Pile Groups in Sloping Ground Subjected to Liquefaction-Induced Lateral Flow: 1-G Shaking Table Tests." Soils and Foundations 50, no. 2 (April 2010): 261–79. http://dx.doi.org/10.3208/sandf.50.261.
Full text
47
Benítez, Irene, Gladys Velázquez, Katherine Alfonzo, Patricia Giménez, Fabiola Martínez, Gabriela Ávila, Natalia Cabrera, Mónica Rodríguez, Jorge Canese, and Zoilo Morel. "Frequency of Colonization and Sensitivity of Staphylococcus aureus in a group of health children in Asunción." Pediatría (Asunción) 44, no. 3 (December 30, 2017): 226–32. http://dx.doi.org/10.18004/ped.2017.diciembre.226-232.
Full text
48
Kotrekhova, L. P., A. A. Vashkevich, E. N. Tsurupa, and P. A. Reztsova. "Naftifine hydrochloride (NH) in the treatment of pityriasis versicolor." Vestnik dermatologii i venerologii 92, no. 2 (April 24, 2016): 103–9. http://dx.doi.org/10.25208/0042-4609-2016-92-2-103-109.
Full textAbstract:
Introduction & objectives: The purpose of this study was to demonstrate the efficacy comparability of 1% NH lotion vs. of 1% NH cream (exoderil, Sandoz) in the treatment of pityriasis versicolor. Material & methods. 71 patients with pityriasis versicolor were randomly allocated either to receive NH lotion once daily (NH lotion group (п = 35, 38.6 years (95% CI [33,7, 43.5]) or NH cream once daily (NH cream group (п = 36, 40.8 years (95% CI [36,6, 45.0]) for 14 days. Mycological evaluations (microscopy and culture) were performed at weeks 2 and 3, inflammation symptoms evaluations were scored at day 3, weeks 2 and 3 after start of the therapy. Overall cure rates assessment included results of mycological, clinical outcomes and safety evaluation. Results. There was no difference between groups in mycological cure rates (94% vs 92%) and inflammation regression (97% vs 97%). Overall cure rate was 91% and 92% of patients in NH lotion and NH cream groups respectively (p = 0,97). Conclusion. 1% NH lotion and 1% NH cream are effective in the treatment of pityriasis versicolor.
49
Coates, L. C., M. Nissen, C. El Baou, J. Zochling, A. Marchesoni, S. Liu Leage, E. Soriano, V. F. Azevedo, K. Machold, and C. Sapin. "FRI0332 EVALUATION OF THE INDIVIDUAL COMPONENTS OF ACR50+PASI100 AND MDA AT WEEK 24 FROM THE SPIRIT-H2H TRIAL COMPARING THE EFFICACY AND SAFETY OF IXE VERSUS ADA IN PATIENTS WITH PSA NAÏVE TO BDMARDS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 758.1–758. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2830.
Full textAbstract:
Background:Psoriatic arthritis (PsA) is a chronic systemic disease with manifestations affecting musculoskeletal and extra-articular domains. Treatment and assessment of response are therefore major challenges in routine clinical practice. Minimal disease activity (MDA) is a multidimensional endpoint that can define a treatment target1. In SPIRIT-H2H2, a head-to-head clinical trial comparing the efficacy and safety of ixekizumab (IXE) versus) to adalimumab (ADA), the percentage of patients simultaneously achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100), was the primary endpoint in order to reflect improvement in two domains of PsA.Objectives:To evaluate how individual components of the simultaneous achievement of ACR50 and PASI100 compare with those of MDA at week 24.Methods:Patients with active PsA (defined as those with a tender joint count [TJC] ≥ 3/68, a swollen joint count [SJC] ≥ 3/66 and a body surface area [BSA] of active plaque psoriasis ≥ 3%) were randomised 1:1 to approved dosing (according to baseline psoriasis involvement) of IXE or ADA in SPIRIT-H2H, an open label, assessor-blinded study.The proportion of patients meeting each criterion of the composite endpoints was calculated for the intent-to-treat ([ITT], N=566) population and the population of MDA responders at Week 24 (N=235). Missing individual responses were imputed with non-responder status. Spidergrams were generated using SAS 9.4.Results:For both the overall ITT population and the MDA responders population, the use of PASI≤1 or BSA≤3% in the skin-related component of the MDA contributed to the higher response rate relative to the PASI100 response. Thus, the PASI100 response is a more stringent endpoint. Proportions of responders are similar across MDA and ACR50+PASI100 individual components for HAQ and SJC. The high baseline TJC levels (mean TJC: IXE=19.1, ADA=21.3) as opposed to lower levels observed for baseline SJC (mean SJC: IXE=10.1, ADA=10.7) made MDA-TJC criterion (≤1) more difficult to achieve than the equivalent criterion of the ACR50+PASI100 endpoint.Conclusion:Despite the differences in criteria definitions, there are consistent response patterns in the individual components of the simultaneous ACR50+PASI100 and MDA endpoints in particular for the peripheral arthritis domain.References:[1]Smolen, Josef S et al. “Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.”Annals of the rheumatic diseasesvol. 77,1 (2018): 3-17.[2]Mease PJ The SPIRIT H2H study group, et al. “A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.”Annals of the Rheumatic Diseases2020;79:123-131.Disclosure of Interests:Laura C Coates: None declared, Michael Nissen Grant/research support from: Abbvie, Consultant of: Novartis, Lilly, Abbvie, Celgene and Pfizer, Speakers bureau: Novartis, Lilly, Abbvie, Celgene and Pfizer, Celine El Baou Consultant of: Eli Lilly and Company, Jane Zochling Employee of: Jannssen Cilag, Speakers bureau: Janssen Cilag, AbbVie, Novartis, UCB, BMS, Eli Lilly, Antonio Marchesoni Speakers bureau: Abbvie, Pfizer, UCB, Novartis, Celgene, Eli Lilly, Soyi Liu Leage Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Enrique Soriano Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Consultant of: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc, Sandoz, Speakers bureau: AbbVie, Amber, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer Inc, Roche, Valderilio F Azevedo Grant/research support from: Abbvie, Janssen, Bristol-Myers Squibb, Boehringer-Ingelheim, Lilly and Novartis, Consultant of: Lilly, Novartis, Janssen, Boehringer-Ingelheim, Amgen, Pfizer and Abbvie, Speakers bureau: Sandoz, Celltrion, Lilly, Novartis, Janssen, Boehringer-Ingelheim, Amgen, Pfizer and Abbvie, Klaus Machold Grant/research support from: AbbVie, MSD, UCB, Consultant of: Arsanis, Astro, Baxter, BMS, Celgene, Eli-Lilly, MSD, Pfizer, Roche, Novartis, Sandoz, Speakers bureau: MSD, Pfizer, BMS, Janssen-Cilag, Sandoz, Novartis, Eli-Lilly, Christophe Sapin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company
50
Benamar, S., C. Lukas, C. Daien, C. Gaujoux-Viala, L. Gossec, A. C. Rat, B. Combe, and J. Morel. "OP0098 POLYPHARMACY IS ASSOCIATED WITH A POORER TREATMENT RESPONSE AND INCREASED RISK OF ADVERSE EVENTS IN EARLY RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 54.1–54. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3213.
Full textAbstract:
Background:Polypharmacy is steadily increasing in patients with rheumatoid arthritis (RA). They may interfere with treatment response and the occurrence of serious adverse events. Medications taken by a patient may reflect active comorbidities, whereas comorbidity indices usually used include past or current diseases.Objectives:To evaluate whether polypharmarcy is associated with treatment response and adverse events in an early RA cohort and to establish whether polypharmacy could represent a substitute of comorbidities.Methods:We used data from the French cohort ESPOIR, including 813 patients with early onset arthritis. Patients included the current study had to start their first disease modifying anti-rheumatic drug (DMARD) within 24 months of inclusion in the cohort. Disease activity data were collected at one, five and ten years from the initiation of the first DMARD. For each patient, treatments were collected at baseline and at five years. Medications count included all specialties other than background RA therapy, analgesics/NSAIDs and topicals. Polypharmacy was defined as a categorical variable based on the median and tertiles of distribution in the cohort. Treatment response was assessed by achieving DAS28 ESR remission (REM) at 1 year, 5 years and 10 years from the initiation of the first DMARD. The occurrence of severe adverse events (SAE) was measured by the occurrence of severe infection, hospitalization, or death during the 10-year follow-up. The association between patient’s characteristics and achievement of REM and occurrence of SAE were tested in univariate analysis. A logistic regression model was used to evaluate associations between polypharmacy and REM at 1 year, 5 years and 10 years (we used baseline polypharmacy for the 1-year analysis and five years polypharmacy for the 5- and 10-years analyses). Multivariate adjustment was made for age, sex, BMI, duration of disease, initial DAS28 ESR, initial HAQ, smoking status, rheumatic disease comorbidity index (RDCI).Results:The proportion of patients who achieved REM one year after the initiation of the first DMARD was 32.1% in the polypharmacy according to the median group (patients taken ≥2 medication) versus 67.9% in the non-polypharmacy group (p=0.07). At 5 years after the first DMARD, the proportion of patients with REM was 45.0% in the polypharmacy group versus 56.3% in the non-polypharmacy group (p=0.03). At 10 years the proportion of patients with REM was 32.5% in the polypharmacy group versus 67.5% (p=0.06). Patients who take greater or equal to 2 medications had a 40% lower probability of achieving REM (OR = 0.60 [0.38-0.94] p = 0.03) at 5 years from the first DMARD (if RDCI index was not included in the model). At 10 years, patients receiving multiple medications had a 43% lower probability of achieving REM (OR = 0.57 [0.34-0.94] p = 0.02). SAE incidence was 61 per 1000 patient-years. For patients who developed SAE all causes 71.4% where in the polypharmacy group versus 57.8% were in the non-polypharmacy group (p = 0.03; univariate analysis). These results are no longer significant after adjustment for comorbidities indices.Conclusion:In this early RA cohort, polypharmacy is associated with a poorer treatment response and increased risk of adverse events. Polypharmacy may represent a good substitute of comorbidities for epidemiological studies.Acknowledgements:We are grateful to Nathalie Rincheval (Montpellier) who did expert monitoring and data management and all theinvestigators who recruited and followed the patients (F. Berenbaum, Paris-Saint Antoine; MC. Boissier, Paris-Bobigny; A. Cantagrel, Toulouse; B. Combe, Montpellier; M. Dougados, Paris-Cochin; P. Fardellone and P. Boumier, Amiens; B. Fautrel, Paris-La Pitié; RM. Flipo, Lille; Ph. Goupille, Tours; F. Liote, Paris- Lariboisière; O. Vittecoq, Rouen; X. Mariette, Paris-Bicêtre; P. Dieude, Paris Bichat; A. Saraux, Brest; T. Schaeverbeke, Bordeaux; and J. Sibilia, Strasbourg).The work reported on in the manuscript did not benefit from any financial support. The ESPOIR cohort is sponsored by the French Society for Rheumatology. An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. Pfizer, Abbvie, Lilly and more recently Fresenius and Biogen also supported the ESPOIR cohort.Disclosure of Interests:Soraya Benamar: None declared, Cédric Lukas Speakers bureau: Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, Consultant of: Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, Grant/research support from: Pfizer, Novartis and Roche-Chugai, Claire Daien Speakers bureau: AbbVie, Abivax, BMS, MSD, Roche, Chugai, Novartis, Pfizer, Sandoz, Lilly, Consultant of: AbbVie, Abivax, BMS, MSD, Roche, Chugai, Novartis, Pfizer, Sandoz, Lilly, Cécile Gaujoux-Viala Speakers bureau: Abbvie, BMS, Celgene, Janssen, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi, Roche-Chugai, UCB, Consultant of: Abbvie, BMS, Celgene, Janssen, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Sanofi, Roche-Chugai, UCB, Grant/research support from: Pfizer, Laure Gossec Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis et UCB, Consultant of: AbbVie, Amgen, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis et UCB, Anne-Christine Rat Speakers bureau: Pfizer, Lilly, Consultant of: Pfizer, Lilly, Bernard Combe Speakers bureau: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi;, Consultant of: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi;, Grant/research support from: Novartis, Pfizer, and Roche-Chugai., Jacques Morel Speakers bureau: Abbvie, BMS, Lilly, Médac, MSD, Nordic Pharma, Pfizer, UCB, Consultant of: Abbvie, BMS, Lilly, Médac, MSD, Nordic Pharma, Pfizer, UCB, Grant/research support from: BMS, Pfizer